Engineered Sialoglycan-Binding Probes for Selective Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective tools for detecting sialoglycans, particularly α2,3 and α2,6 sialoglycans, which are critical for immunological recognition and cancer biomarkers, due to limited useful antibodies and probes with sufficient selectivity and stability.
Innovation Solution
Engineered sialoglycan-binding probes with specific mutations in the CD, EF, or FG loop of Siglec-like serine-rich repeat adhesins, such as E285R or N333P substitutions, and chimeric constructs with loops from other Siglecs, are developed to enhance binding selectivity for tri-, tetra-, penta-, hexa-, and octa-saccharides, including sulfated derivatives, and α2,3 or α2,6 sialoglycans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional antibodies are used for sialoglycan detection, then detection capability is provided, but selectivity and stability are insufficient
Solution Approach 1:
The patent modifies the binding properties of Siglec-like adhesins by introducing specific mutations in the CD, EF, and FG loops of the V-set Ig fold. These parameter changes in the protein structure enable the probes to achieve both high selectivity for specific sialoglycans (α2,3 or α2,6 linkages) and high stability, resolving the contradiction between detection capability and reliability.
2Measurement precision
If probes with high binding selectivity are developed, then detection precision improves, but device complexity increases
Solution Approach 1:
The patent divides the Siglec-like adhesin into functional segments, specifically targeting the CD, EF, and FG loops as independent mutation sites. This segmentation allows for systematic optimization of binding selectivity through targeted mutations in these specific regions, achieving high precision without requiring complete redesign of the entire protein structure.
Solution Approach 2:
The patent applies local quality changes by introducing specific mutations only in the CD, EF, and FG loops of the V-set Ig fold, while maintaining the overall protein structure intact. This localized modification approach achieves high binding selectivity for specific sialoglycans without increasing overall device complexity.
3Reliability
If chimeric constructs with loops from other Siglecs are created, then binding affinity for specific sialoglycans increases, but manufacturing complexity increases
Solution Approach 1:
The patent creates chimeric Siglec-like adhesins by combining the V-set Ig fold framework with CD, EF, and FG loops from different Siglec sources. This universal framework approach allows a single base structure to support multiple loop configurations, enabling production of various high-affinity probes through simple loop swapping rather than complete protein synthesis, thus reducing manufacturing complexity.
Data Source
AI summary
Disclosed are compositions and methods related to the use of sialoglycan as markers for the diagnosis and prognosis of cancers and inflammatory conditions. In one aspect, also disclosed herein are engineered probes and chimeric probes with differential binding ability to sialoglycans.